Why Pliant Therapeutics Stock Is Surging Today
Shares of Pliant Therapeutics (NASDAQ: PLRX), a clinical-stage biotech company, are on the move following a clinical trial readout for its lead candidate, PLN-74809. Investors impressed with the positive results drove the stock 23% higher shortly after the market opened this morning. The stock was up 11.1% as of 11:23 a.m. EDT on Tuesday.
Pliant's developing PLN-74809 for people who experience progressive lung scarring that occurs for reasons medicine can't explain yet. Idiopathic pulmonary fibrosis (IPF) is lethal, but there aren't any available treatments to prevent its progression.
Image source: Getty Images.
Source Fool.com
